Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26101-26110 Newer>

The Motley Fool September 14, 2007 Ryan Fuhrmann	Fool on the Street: Columbia Sportswear Stays Stylish CEO Tim Boyle talks to investors about Columbia Sportswear's aggressive margin structure, constant focus on creative products, and marketing control.
The Motley Fool September 14, 2007 Toby Shute	Alcoa Chucks a Chunk o' Chalco Alcoa sells its 8% stake in Chinese mining company Chalco. Financially, it has been a profitable deal for the company, strategically, it hasn't gone as well.
The Motley Fool September 14, 2007 Anders Bylund	Fool on the Street: Texas Instruments on Target In its mid-quarterly conference call, TI informs investors it has restarted some manufacturing facilities in anticipation of increased demand.
The Motley Fool September 14, 2007 Brian Lawler	Is Flamel Catching On? Flamel Technologies announces a deal with Wyeth to develop an improved formulation of a drug, but the financials, and details, remain secret.
The Motley Fool September 14, 2007 Brian Lawler	"Dear Doctor" Letter Spells Trouble for Cephalon Cephalon sends a letter to health-care practitioners warning of the dangers of misusing one of its lead drugs, Fentora. Investors, take note.
The Motley Fool September 14, 2007 Emil Lee	Fool on the Street: Capital One's Crystal Ball Capital One explains why the subprime mess has not spilled over into other consumer lending areas. Investors should take note.
The Motley Fool September 14, 2007 Brian Orelli	Good News About Propecia and Cancer Recent studies show that Merck's hair-loss remedy doesn't cause cancer. Instead, it helps doctors find tumors. Does this present another revenue stream for the drug as a cancer preventative?
The Motley Fool September 14, 2007 Lawrence A. Rothman	Fool on the Street: Coach in the Fast Lane Accessorizing is paying off for Coach. The company has been growing its top and bottom lines rapidly and with remarkable consistency; it recently completed its 22nd quarter of at least 20% sales growth and 30% earnings growth.
The Motley Fool September 14, 2007 Brian Lawler	FDA Keeps Adolor Waiting Adolor and partner GlaxoSmithKline continue playing the FDA waiting game, as the agency has still not decided whether to allow clinical trials of Adolor's top drug to continue.
The Motley Fool September 14, 2007 Mac Greer	Fool Video: Should Sirius Lose the Satellite? Are Wi-Fi and WiMAX in Sirius Satellite Radio's future? This question is addressed in this video discussion.
<Older 26101-26110 Newer> Return to current articles.